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intensive care unit bed). The mean direct medical expenditures
for one patient is 25,858 CZK (€1,034) per year. CONCLU-
SIONS: Based on data from Institute of Health Information and
Statistics of the Czech Republic in 2006 there were 678 760 type
2 diabetic patients in our country. It it roughly 17.5 bilion CZK
(€0.7 bil) per year, counting approximately 20% of total health
care spending in Czech Republic.
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OBJECTIVES: To estimate the annual medical costs attributable
to obesity in diabetic patients. METHODS: This cross-sectional
analysis was based on the 2001–2005 Medical Expenditure Panel
Survey data, a nationally representative sample of the U.S. non-
institutionalized population. A total of 4880 diabetic patients
were identiﬁed based on the ICD-9-CM code:250 after excluding
patients with pregnancy, malignancy, kidney dialysis, immuno-
deﬁciency, or >75years old. Diabetic patients were classiﬁed as
normal (body mass index(BMI):18.5–<25), overweight(BMI:25–
<30), or obese(BMI:30). Medical costs included costs associ-
ated with any treatments except dental problems and injuries.
The parameters for obese patients were estimated using a gener-
alized linear model with a log link function and a gamma distri-
bution after adjusting for the demographic variables. The mean
medical cost was predicted for normal-weight patients using the
parameters estimated from the obese patients. The difference
between the predicted and the observed costs in normal weight
patients was the medical costs attributable to obesity. All costs
were converted to 2005 U.S. dollars using price indices. Data
were analyzed using SAS and SUDAAN. RESULTS: The age-
adjusted prevalence of the study diabetic patients was 2.1% in
normal-weight, 3.9% in overweight, and 9.7% in obese patients
respectively. The average attributable costs to obesity in diabetic
patients were $1,527 (95%CI:$318–$2736). The average attrib-
utable costs to obesity increased as patients became older ($794
for aged 18–50, $1636 for aged 51–64, and $2044 for aged
65–74) and were higher in women ($2679) than men ($139), and
in private insurance ($2185) compared to public insurance
($591). CONCLUSIONS: The prevalence of diabetes in obese
people was approximately ﬁve times higher than in normal-
weight people. The medical costs for obese patients with diabetes
were signiﬁcantly higher than in normal weight patients. The
effective public health intervention aimed at controlling weight in
diabetic patients is recommended to reduce the extra economic
burden of obesity.
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OBJECTIVES: To estimate and compare the economic implica-
tions of insulin glargine (GLAR) and detemir (DET) therapy
initiation in a population with type 2 diabetes mellitus (T2DM)
with a one year time horizon, from major insurers perspectives in
Argentina (union-based and private HMOs). METHODS: Clini-
cal and efﬁcacy parameters and their distributions were based on
Rosenstock’s article (2008), a 52-week randomized treat-to-
target trial which compared clinical outcomes following supple-
mentation of oral glucose-lowering drugs with basal insulin
analogues, DET and GLAR, in T2DM patients. Resource use and
cost values, as well as their distributions, were obtained from
Argentinean published literature, tariffs, databases, experts’
opinion and the international literature. Costs are expressed in
local currency, year 2008 (exchange rate 1€ = 4.79ARG$). Vari-
ability was incorporated in insulin, needles and strips costs,
proportion of DET patients with once daily injection and GLAR
and DET dose per kilogram. Probabilistic sensitivity analysis
(PSA) was carried out based on Monte Carlo simulations with
10,000 iterations. Linear regression analysis was carried out in
order to gauge the relative inﬂuence on the results related to the
uncertainty around each parameter. RESULTS: Annual mean
cost was $2630 for GLAR and $4,092 for DET, implying a 36%
(95%CI 33.2%; 37.9%) total cost saving with GLAR ($1462). A
total of 82.7% of this difference was explained by the lower
average daily dose requirement with GLAR (GLAR 26 UI vs.
DET 42 UI). Savings in test strips, and needles explained 10.2%
and 7.1% of the total difference. In the regression analysis, the
most important parameters explaining variability in total cost
savings were the proportion of DET patients requiring twice
daily injections followed by the insulin dose per patient. CON-
CLUSIONS: In Argentina, Insulin Glargine was associated with
a cost saving of more than one third compared to the use of
Insulin Detemir. Sensitivity analyses conﬁrmed the robustness of
this result.
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OBJECTIVES: To compare the economic impact of the treatment
of acromegaly with two different somatostatin analogues in
Brazil, after the decision of reimbursement of the therapeutic
class by the Brazilian Public Health Care System (SUS) in 2002.
METHODS: Acromegaly treatment cost estimation was based
on secondary data and on a decision analytical model developed
from the Brazilian Public Health Care System Clinical Guideline
for Acromegaly. The strategies of using somatostatin analogues
in depot presentations (octreotide LAR or lanreotide SR) were
compared. The model followed a hypothetical cohort of 276
patients diagnosed with acromegaly for two years. Costing
included direct medical costs, composed by drugs, consultations,
monitoring tests, radiotherapy and hospitalisation, under the
Brazilian Public Health Care System perspective. Data were
extracted from national and international literature, and from
administrative ofﬁcial databases (Ambulatory Information
System, Hospital Information System, Mortality Information
System). Costs are reported in 2005 Reais (R$) and Euros (€).
Ofﬁcial exchange rate was used for currency conversion (2.77
BRL = 1 EUR, Brazilian Central Bank). Sensitivity analysis was
conducted. RESULTS: Octreotide LAR treatment strategy pre-
sented net savings of R$10,448,324 (€3,771,958) to the Brazilian
Public Health Care System when compared to lanreotide SR
treatment strategy in a period of two years. Average annual cost
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